Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMolina Nexviazyme Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C21948-A

    Nexviazyme Coverage for Late-Onset Pompe Disease

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C21948-A alerts

    Get alerted when Policy C21948-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of intravenous Nexviazyme (avalglucosidase alfa-ngpt) for members aged 1 year and older with documented late-onset Pompe disease. It establishes diagnostic, documentation, prescriber, dosing, continuation, administration-site, and nonconcurrent-therapy requirements.

    Policy Summary
    PayerMolina Healthcare
    PolicyNexviazyme Coverage for Late-Onset Pompe Disease
    Policy CodePolicy C21948-A
    Change TypeNo material clinical or coverage changes
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit prior authorization for members aged 1 year and older with late-onset Pompe disease.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥1 yearMinimum age
    12 monthsInitial authorization
    12 monthsContinuation authorization
    Every 2 weeksAdministration frequency

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J0219
    HCPCS code

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met for initial therapy:

    Initial therapy

    • Covered indication

      • Documented diagnosis of late-onset Pompe disease (LOPD).
      • Diagnostic confirmation

        • Enzyme assay shows deficient acid alpha-glucosidase (GAA) activity in blood, skin, or muscle.
        • Genetic testing shows a mutation in the GAA gene.
      • Baseline disease assessment

        • Baseline percent-predicted forced vital capacity (FVC) is documented.
        • Baseline walking distance or 6-minute walk test (6MWT) is documented.

          The 6MWT is not required for members who are not old enough to walk.

        • Gastrointestinal symptoms are documented.
      • Member is 1 year of age or older.Age >= 1 year
      • Nexviazyme is prescribed by, or in consultation with, a metabolic specialist, endocrinologist, biochemical geneticist, or physician experienced in managing Pompe disease.

    Continuation Therapy

    Covered for continuation when ALL of the following are met:

    Continuation therapy

    • There is no evidence of intolerable adverse effects or drug toxicity.
    • Documentation demonstrates a beneficial response to therapy compared with the pretreatment baseline, shown by stabilization or improvement in FVC and/or 6MWT and in signs or symptoms of the condition, such as gastrointestinal symptoms.

    Not Medically Necessary or Investigational

    Not covered when the requested use is outside the covered indication:

    Experimental or investigational use

    • All other uses of Nexviazyme (avalglucosidase alfa-ngpt), including uses other than treatment of late-onset Pompe disease, are considered experimental or investigational and follow Molina's Off-Label policy.

    Nexviazyme must not be used concurrently with Lumizyme (alglucosidase) or with the combination of Pombiliti (cipaglucosidase) and Opfolda (miglustat).

    Uses of Nexviazyme outside the covered late-onset Pompe disease indication are considered experimental or investigational and follow Molina’s Off-Label policy.

    Billing and Coding

    Covered HCPCS CodesHCPCSCovered
    J0219Injection, avalglucosidase alfa-ngpt, 4 mg
    Neutral HCPCS CodesHCPCS
    J0219Injection, avalglucosidase alfa-ngpt, 4 mg

    Provider Requirements and Administration

    Prior Authorization

    Initial Prior Authorization

    Prior authorization is required for Nexviazyme for eligible members with late-onset Pompe disease (LOPD). Initial authorization is available for 12 months when the member is at least 1 year of age and the request meets the diagnostic and baseline assessment requirements.

    • FDA-approved indication: patients 1 year of age and older with LOPD (lysosomal acid alpha-glucosidase [GAA] deficiency).
    • Initial authorization duration: 12 months.
    Prior Authorization

    Reauthorization Requirements

    For continuation, the prescriber must attest, or the clinical reviewer must find, no intolerable adverse effects or drug toxicity. Documentation must also show a beneficial response compared with pretreatment baseline.

    • Continuation authorization duration: 12 months.
    • Beneficial response may be demonstrated by stabilization or improvement in FVC and/or 6MWT and signs or symptoms of Pompe disease, such as gastrointestinal symptoms.

    Clinical Background

    Late-onset Pompe disease is an autosomal recessive deficiency of lysosomal acid alpha-glucosidase (GAA). The deficiency causes glycogen to accumulate in cells, resulting in tissue damage. Juvenile- and adult-onset disease typically causes progressive skeletal muscle weakness, often in a limb-girdle distribution, and may progress to respiratory failure.

    Enzyme replacement therapy provides an external source of GAA. In late-onset Pompe disease, treatment has been associated with improvements in muscle strength, mobility, and lung function.

    Definitions

    Pompe disease
    DefinitionA lysosomal acid alpha-glucosidase (GAA) deficiency disorder caused by mutations in the GAA gene.
    Alternate namesAcid maltase deficiency; glycogen storage disease type II (GSD II).
    InheritanceAutosomal recessive disorder.
    Late-onset Pompe disease (LOPD)
    DefinitionThe juvenile or adult form of GAA deficiency.
    Characteristic clinical featuresGenerally characterized by skeletal myopathy, usually in a limb-girdle distribution, and progressive weakness.
    Clinical course

    Initial Therapy Criteria

    Initial Therapy

    Initial therapy requires ALL of the following:

    Initial therapy

    • Diagnosis and confirmation

      • The member has a documented diagnosis of late-onset Pompe disease (LOPD).
      • ONE of

        • An enzyme assay shows deficient acid alpha-glucosidase (GAA) activity in the blood, skin, or muscle.
        • Genetic testing shows a mutation in the GAA gene.
    • ONE of the following baseline assessments

    Continuation of Therapy

    Continuation of Therapy

    Continuation therapy requires ALL of the following:

    Continuation of therapy

    • The prescriber attests to, or the clinical reviewer has found, no evidence of intolerable adverse effects or drug toxicity.
    • Documentation shows a beneficial response to therapy compared with the pretreatment baseline, demonstrated by stabilization or improvement in FVC and/or 6MWT and signs or symptoms of the condition, such as gastrointestinal symptoms.

    Dose and Quantity Limits

    Nexviazyme dosing limits
    MedicationNexviazyme (avalglucosidase alfa-ngpt).
    Members weighing 30 kg or more20 mg/kg of actual body weight every two weeks.
    Members weighing less than 30 kg40 mg/kg of actual body weight every two weeks.

    Administration Site of Care

    Note

    Use a non-hospital infusion facility

    Infused medication is recommended to be administered under pharmacy or medical benefit coverage in a non-hospital facility-based location according to Molina’s Site of Care program. The Site of Care Utilization Management Policy applies to Nexviazyme.

    • Confirm the administration location and applicable benefit coverage before infusion.
    Policy Summary
    PayerMolina Healthcare
    PolicyNexviazyme Coverage for Late-Onset Pompe Disease
    Policy CodePolicy C21948-A
    Change TypeNo material clinical or coverage changes
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit prior authorization for members aged 1 year and older with late-onset Pompe disease.
    SourceLink
    On This Page
    Coverage CriteriaBilling and CodingProvider Requirements and AdministrationClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation of TherapyDose and Quantity LimitsAdministration Site of Care
    Documentation Required

    General Supporting Documentation

    Submit complete medical rationale and supporting records with the request. Molina may require additional documentation to evaluate medical necessity, non-investigational status, benefit eligibility, and appropriate billing.

    • Patient medical records and relevant test results.
    • Credentials of the provider ordering or performing the drug or service.
    • Additional information may be requested on a case-by-case basis.
    Documentation Required

    Diagnostic Confirmation

    Document confirmation of Pompe disease using one of the accepted diagnostic methods.

    • Enzyme assay showing deficient acid alpha-glucosidase (GAA) activity in blood, skin, or muscle.
    • Genetic testing showing a mutation in the GAA gene.
    Documentation Required

    Baseline Disease Assessment

    Include pretreatment baseline disease measures to support the medical-necessity review and future response assessment.

    • Baseline percent-predicted forced vital capacity (FVC).
    • Baseline walking distance or 6-minute walk test (6MWT).
    • Baseline gastrointestinal symptoms.
    • The 6MWT is not required for members who are too young to walk.
    Documentation Required

    Consultation Notes Required

    When Nexviazyme is prescribed in consultation, submit the consultation documentation with both the initial request and each reauthorization request.

    • Consultation notes must accompany the initial request.
    • Consultation notes must accompany reauthorization requests.
    Documentation Required

    Continuation Response Documentation

    For continuation review, document that therapy remains tolerated and is producing a beneficial response compared with the member’s pretreatment baseline.

    • No evidence of intolerable adverse effects or drug toxicity.
    • Document stabilization or improvement in FVC and/or 6MWT.
    • Document stabilization or improvement in signs and symptoms, including gastrointestinal symptoms when applicable.
    Billing Rule

    Weight-Based Dosing Information

    Provide the member-specific actual body weight when reviewing weight-based Nexviazyme dosing.

    • Members weighing 30 kg or more: 20 mg/kg of actual body weight every 2 weeks.
    • Members weighing less than 30 kg: 40 mg/kg of actual body weight every 2 weeks.
    Note

    Infusion Safety and Monitoring

    Administer Nexviazyme where appropriate emergency equipment and trained personnel are readily available. Monitor patients during the infusion, with more frequent vital-sign monitoring for members at increased risk of serious cardiac or respiratory complications.

    • Emergency equipment should be readily available during avalglucosidase alfa administration.
    • Patients susceptible to fluid-volume overload, with acute underlying respiratory illness, or with compromised cardiac or respiratory function may require fluid restriction and more frequent monitoring of vital signs.
    • Patients with an acute underlying illness may be at greater risk for infusion-associated reactions.
    • Advanced Pompe disease with compromised cardiac or respiratory function may increase the risk of severe complications.
    • Consider pretreatment with antihistamines, antipyretics, and/or corticosteroids before administration.
    Denial Risk

    Management of Severe Infusion Reactions

    If a severe hypersensitivity reaction or severe infusion-associated reaction occurs, stop or consider immediately discontinuing avalglucosidase alfa and initiate appropriate medical treatment. Carefully assess the benefits and risks before readministering therapy.

    • For severe hypersensitivity, including anaphylaxis, discontinue avalglucosidase alfa immediately and initiate appropriate medical treatment.
    • Desensitization to avalglucosidase alfa may be considered after a severe hypersensitivity reaction.
    • For severe infusion-associated reactions, consider immediate discontinuation, appropriate medical treatment, and a risk-benefit assessment for readministration.
    Denial Risk

    Noncovered or Investigational Use

    Uses of Nexviazyme other than the covered FDA-approved indication for patients at least 1 year of age with LOPD are considered experimental or investigational and are handled under Molina’s Off-Label policy.

    • Covered indication: late-onset Pompe disease caused by lysosomal acid alpha-glucosidase (GAA) deficiency.
    • Other uses follow the applicable Off-Label policy.
    Denial Risk

    Concurrent Pompe Therapies Prohibited

    Do not use Nexviazyme concurrently with another listed enzyme-replacement or Pompe therapy.

    • Do not use concurrently with Lumizyme (alglucosidase).
    • Do not use concurrently with Pombiliti (cipaglucosidase) and Opfolda (miglustat).
    Documentation Required

    Qualified Prescriber Requirement

    Nexviazyme must be prescribed by, or in consultation with, a qualified clinician experienced in Pompe disease management.

    • Eligible prescribers include a metabolic specialist, endocrinologist, biochemical geneticist, or physician experienced in managing Pompe disease.
    • If prescribed in consultation, submit consultation notes with the initial request and reauthorization requests.
    Denial Risk

    Insufficient Medical Documentation

    Missing or inadequate documentation may result in delayed review, denial, non-reimbursement, or other appropriate action. Molina may determine that the requested drug is not medically necessary, investigational, experimental, or within the member’s benefit scope when the submitted records do not support the request.

    • Provide accepted diagnostic confirmation of GAA deficiency or a GAA gene mutation.
    • Provide baseline FVC, walking distance or 6MWT when applicable, and gastrointestinal symptoms.
    • Provide required continuation response and tolerability documentation.
    • Provide provider credentials and consultation notes when applicable.
    A protracted course that may lead to respiratory failure.
    6-minute walk test (6MWT)
    DefinitionA test measuring walking distance over six minutes.
    UseUsed as a baseline or follow-up assessment when the member is able to walk.
    Age-related exceptionThe 6MWT is excluded for members at an age not able to walk.
    Baseline percent-predicted forced vital capacity (FVC) is documented.
  1. Baseline walking distance or 6-minute walk test (6MWT) is documented.

    The 6MWT is not required for members at an age unable to walk.

  2. Gastrointestinal symptoms are documented.
  3. The member is 1 year of age or older.Age >= 1 year
  4. The prescription is written by, or provided in consultation with, a metabolic specialist, endocrinologist, biochemical geneticist, or physician experienced in the management of Pompe disease.